How Kelly Chibale Redrew the Map of Global Drug Discovery From Africa

For most of the modern pharmaceutical era, the map of drug discovery has been drawn with a striking asymmetry. Target identification, high-throughput screening, medicinal chemistry and translational pharmacology were concentrated in North America, Western Europe and parts of East Asia, while sub-Saharan Africa — the region carrying the world’s heaviest burden of infectious diseases such as malaria and tuberculosis — contributed mainly epidemiological data, clinical trial infrastructure and biological samples. The molecules that might one day treat African patients were, almost without exception, designed, synthesised and optimised thousands of kilometres away. A new perspective article, published in Frontiers in Drug Discovery by researchers from Cameroon, Zambia, Ghana, Kenya and Zimbabwe, argues that this geography is now being actively rewritten, and that the career of one South African chemist offers the clearest blueprint for how the shift can be sustained.

The subject of the analysis is Professor Kelly Chibale, a Zambian-born synthetic organic and medicinal chemist at the University of Cape Town whose personal history mirrors the scientific problem he set out to solve. As a child, he survived several bouts of malaria, including one severe episode that nearly killed him. Trained in chemistry in Zambia, the United Kingdom — including a visiting fellowship at Pfizer in Sandwich — and the United States, he specialised in small-molecule drug discovery for cardiovascular disease, including hypertension, before turning his focus to infectious diseases: malaria, tuberculosis, schistosomiasis and, more recently, antibiotic-resistant microbial infections. The authors of the perspective, led by Fidele Ntie-Kang of the University of Buea, contend that Chibale’s most transformative achievement is not a single molecule but an institution: the Holistic Drug Discovery and Development Centre, known as H3D, founded in 2010 as the first fully integrated drug discovery platform on the African continent.

What made H3D structurally innovative was its pipeline-oriented design. Rather than operating as a fragmented, grant-driven academic laboratory, the centre co-located screening technologies, biology, medicinal chemistry, in vitro ADME systems, drug metabolism and pharmacokinetics (DMPK), early safety and toxicology assessment, and translational project management within a single institutional framework. This co-location enables seamless progression from hit identification through lead optimisation to candidate selection, supporting the iterative, data-driven decision-making that characterises industrial discovery environments. The result, the perspective argues, is a cohesive discovery setting capable of delivering translational outputs that meet industry-level standards while remaining rooted in an African academic context — a proof of concept that end-to-end pharmaceutical innovation can be conducted on the continent.

The scientific credibility of that model rests on rigorous medicinal chemistry. Chibale’s antimalarial programmes have been distinguished by the iterative refinement of structure–activity relationships, allowing progressive optimisation of compound potency and selectivity, alongside careful tuning of physicochemical properties to enhance drug-likeness, solubility and permeability. Central to the H3D strategy has been the early integration of ADME profiling, ensuring that compounds are evaluated not only for biological activity but for their behaviour in living systems. By aligning compound optimisation with clearly defined target product profiles, the projects maintained a translational focus from the outset. Because malaria drug discovery frequently relies on phenotypic screening — the complexity of parasite biology makes target validation difficult — H3D combined whole-cell phenotypic screening with rational medicinal chemistry refinement, balancing empirical screening with mechanistic insight, conducting target deconvolution to elucidate mechanisms of action, and pursuing target-based discovery in parallel.

The defining milestone came with MMV390048, a novel first-in-class small-molecule inhibitor of Plasmodium phosphatidylinositol 4-kinase, advanced from an international effort led out of Africa at H3D in partnership with the Medicines for Malaria Venture into First-in-Human studies conducted at the University of Cape Town, and subsequently into phase 2 clinical trials. The significance, the authors write, is multidimensional. Scientifically, it demonstrated a functional and coherent hit-to-lead discovery capability within an African setting. Institutionally, it validated the H3D operational model as a sustainable platform for end-to-end discovery. Symbolically, it marked a paradigm shift: Africa could originate pharmaceutical innovation rather than serving solely as a site for clinical trials and downstream validation. Chibale’s contributions extend beyond infectious disease — he is a co-inventor on patents for domain-selective inhibitors of angiotensin-I converting enzyme, around which the United Kingdom spin-out company Angiodesign was established.

H3D’s sustainability was engineered as deliberately as its science. The centre operated on a diversified funding model combining government support, philanthropic foundations, product development partnerships, bilateral industry collaborations and competitive international grants. This hybrid architecture minimised dependence on any single funding source, reduced financial vulnerability and enabled long-term strategic planning. Equally consequential was the way the centre redefined academia–industry partnership: negotiations were structured around co-development rather than subcontracting, ensuring shared ownership of scientific direction and outcomes. African investigators contributed meaningfully to strategic priorities and project design, while the partnerships provided access to advanced technologies, industry-standard workflows and global development expertise — strengthening the credibility of African institutions as reliable, competitive contributors to international pharmaceutical research.

But a single centre, however excellent, could not close the continent’s capacity gaps. The logical next step was network expansion, and it came through the Grand Challenges African Drug Discovery Accelerator, or GC ADDA. Its origins trace to seed funding from the Bill and Melinda Gates Foundation under Grand Challenges Africa in 2018 and 2020, awarded to 16 scientists across Africa to pursue structured, collaborative drug discovery with international partners. Many of those initial grantees became founding members of the GC ADDA network, which was established by the H3D Foundation with funding support from the Gates Foundation and LifeArc. The consortium now operates as a pan-African accelerator with representation in four of Africa’s five geographical regions, integrating competitive project selection, milestone-driven funding, access to expertise in medicinal chemistry and DMPK, industry mentorship and translational guidance.

The accelerator model directly targets the persistent

Subject of Research: The role of Professor Kelly Chibale and the H3D Centre in establishing integrated, African-led drug discovery capacity and pan-African innovation networks

Article Title: Redefining the geography of pharmaceutical innovation: Kelly Chibale as a harbinger for integrated drug discovery in Africa

Article References: Ntie-Kang, F., Cheuka, P. M., Amewu, R. K., Kigondu, E. V. M., & Masimirembwa, C. (2026). Redefining the geography of pharmaceutical innovation: Kelly Chibale as a harbinger for integrated drug discovery in Africa. Frontiers in Drug Discovery, 6, Article 1884834. https://doi.org/10.3389/fddsv.2026.1884834

Image Credits: AI Generated

DOI: 10.3389/fddsv.2026.1884834

Keywords: Kelly Chibale, H3D Centre, drug discovery, Africa, GC ADDA, medicinal chemistry, malaria, MMV390048, scientific sovereignty, pharmaceutical innovation, Global South, capacity building